We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+4.6%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$53.3B
AUM Growth
+$1.63B
(+3.2%)
Cap. Flow
-$179M
Cap. Flow
% of AUM
-0.34%
Top 10 Holdings %
Top 10 Hldgs %
17.17%
Holding
3,102
New
155
Increased
2,027
Reduced
775
Closed
131
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Dow Inc
DOW
|
+$67.7M |
| 2 |
Corteva
CTVA
|
+$33.4M |
| 3 |
TCF
TCF Financial Corporation Common Stock
TCF
|
+$19.3M |
| 4 |
Spotify
SPOT
|
+$15.3M |
| 5 |
Amcor
AMCR
|
+$15M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DuPont de Nemours
DD
|
+$62.6M |
| 2 |
Apple
AAPL
|
+$51.5M |
| 3 |
ULTI
Ultimate Software Group Inc
ULTI
|
+$29.7M |
| 4 |
NXP Semiconductors
NXPI
|
+$28.9M |
| 5 |
Microsoft
MSFT
|
+$23.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.25% |
| 2 | Financials | 15.55% |
| 3 | Healthcare | 13.39% |
| 4 | Consumer Discretionary | 10.43% |
| 5 | Industrials | 10.34% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
GFN
2901
DELISTED
General Finance Corporation
GFN
| $117K | ﹤0.01% |
13,939
+1,287
| +10% | +$11.1K |
|
2902
Nature's Sunshine
NATR
$372M
| $116K | ﹤0.01% |
12,442
+218
| +2% | +$2.04K |
|
2903
GSI Technology
GSIT
$233M
| $115K | ﹤0.01% |
+13,377
| New | +$108K |
|
|
BFX
2904
DELISTED
BowFlex Inc.
BFX
| $115K | ﹤0.01% |
51,993
-31,303
| -38% | -$124K |
|
|
ELVT
2905
DELISTED
Elevate Credit, Inc.
ELVT
| $115K | ﹤0.01% |
27,975
+2,479
| +10% | +$11.1K |
|
2906
ADMA Biologics
ADMA
$2.03B
| $114K | ﹤0.01% |
29,398
+6,599
| +29% | +$29.1K |
|
2907
Safe Bulkers
SB
$803M
| $114K | ﹤0.01% |
72,950
+3,420
| +5% | +$5.31K |
|
2908
Solid Biosciences
SLDB
$790M
| $114K | ﹤0.01% |
1,317
+304
| +30% | +$33.2K |
|
|
JNCE
2909
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $114K | ﹤0.01% |
22,935
+3,345
| +17% | +$17.8K |
|
2910
Galectin Therapeutics
GALT
$200M
| $113K | ﹤0.01% |
+27,255
| New | +$118K |
|
2911
Valhi
VHI
$380M
| $113K | ﹤0.01% |
3,164
+260
| +9% | +$7.27K |
|
2912
Alphatec Holdings
ATEC
$1.56B
| $110K | ﹤0.01% |
+24,280
| New | +$90.6K |
|
2913
Lee Enterprises
LEE
$175M
| $110K | ﹤0.01% |
+4,924
| New | +$135K |
|
2914
Aclaris Therapeutics
ACRS
$772M
| $109K | ﹤0.01% |
49,895
+3,933
| +9% | +$21.4K |
|
|
STEX
2915
Streamex Corp
STEX
$78.1M
| $109K | ﹤0.01% |
+1,158
| New | +$84.1K |
|
|
YARW
2916
Yarrow Bioscience, Inc. Common Stock
YARW
$22.4M
| $109K | ﹤0.01% |
5
+2
| +67% | +$49.5K |
|
2917
Kopin
KOPN
$693M
| $108K | ﹤0.01% |
99,399
-66,806
| -40% | -$81.2K |
|
2918
Liquidia Corp
LQDA
$7.46B
| $108K | ﹤0.01% |
+13,525
| New | +$127K |
|
2919
Anavex Life Sciences
AVXL
$273M
| $107K | ﹤0.01% |
+31,829
| New | +$98.9K |
|
2920
Mustang Bio
MBIO
$4.37M
| $106K | ﹤0.01% |
38
+12
| +46% | +$34.2K |
|
|
ZYXI
2921
DELISTED
Zynex
ZYXI
| $105K | ﹤0.01% |
+12,903
| New | +$84.2K |
|
|
ICD
2922
DELISTED
Independence Contract Drilling, Inc.
ICD
| $105K | ﹤0.01% |
3,320
+428
| +15% | +$20.9K |
|
|
MBII
2923
DELISTED
Marrone Bio Innovations, Inc.
MBII
| $105K | ﹤0.01% |
70,226
+2,890
| +4% | +$4.47K |
|
|
SBBP
2924
DELISTED
Strongbridge Biopharma plc.
SBBP
| $105K | ﹤0.01% |
+33,500
| New | +$123K |
|
|
CVIA
2925
DELISTED
Covia Holdings Corporation Common Stock
CVIA
| $105K | ﹤0.01% |
53,470
+15,034
| +39% | +$57.9K |
|
Similar funds
VAM
RhumbLine Advisers's Q2 2019 Portfolio in Review
As of Q2 2019, RhumbLine Advisers held 3,102 positions worth $53.3B, up 3.2% from $51.6B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
RhumbLine Advisers's Q2 2019 filing shows 155 new, 2,027 increased, 775 reduced and 131 closed positions. Its largest new stake was Dow Inc: 1,282,896 shares worth $63.3M. The largest sale was DuPont de Nemours, an estimated $62.6M.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 18% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q2 2019 buy was Dow Inc: 1,282,896 shares worth $63.3M.
- RhumbLine Advisers added most to TCF Financial Corporation Common Stock in Q2 2019, an estimated $19.3M increase.
- RhumbLine Advisers's biggest Q2 2019 reduction was DuPont de Nemours, cutting an estimated $62.6M.
- RhumbLine Advisers fully exited Ultimate Software Group Inc in Q2 2019, selling an estimated $29.7M.
- RhumbLine Advisers's ten largest holdings make up 17% of its $53.3B portfolio in Q2 2019.
- RhumbLine Advisers opened 155 new positions and closed 131 in Q2 2019.
- RhumbLine Advisers's portfolio value rose 3.2% quarter-over-quarter to $53.3B.
Based on RhumbLine Advisers's 13F filing for Q2 2019, filed 14 Aug 2019.